Table 1.
Demographic and clinical characteristics of patients prior to commencement of mepolizumab.
| Variable | Severe Uncontrolled Asthma |
|---|---|
| n = 61 (%) | 61 (100) |
| Age (y.o.) mean (SD) | 45.98 (38.89) |
| <20 y.o. (%) | 5 (8.19) |
| >20 y.o. (%) | 56 (91.81) |
| Sex (Female%/Male%) | 60.65/39.35 |
| BMI mean (SD) | 29.10 (4.04) |
| Smoking | |
| Never smoker | 41 (67.21) |
| Former smoker | 17 (27.86) |
| Smoker | 3 (4.91) |
| Bronchiectasis (Chest CT Scanner) | 3 (4.91) |
| SPT+ HDM and/or SM | 51 (83.6) |
| Allergic Rhinitis (%) | 52 (85.24) |
| Atopic Dermatitis (%) | 9 (14.75) |
| Nasal Polyposis (%) | 22 (36.06) |
| NERD (%) | 11 (18.03) |
| Chronic Rinosinusitis (%) | 17 (27.86) |
| Eosinophilic Esophagitis (%) | 2 (3.2) |
| Food Allergy (%) | 2 (3.2) |
| Asthma Onset at Childhood (%) | 42 (68.85) |
| Family History of Atopy (%) | 49 (80.32) |
SD: Standard deviation of the mean. SPT: Skin Prick Test. HDM: House dust mites (Dermatophagoides spp.) SM: Storage mites (Blomia tropicalis). NERD: NSAID-exacerbated respiratory disease.